Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.70 CAD
Change Today 0.00 / 0.00%
Volume 0.0
RBM On Other Exchanges
Symbol
Exchange
Stuttgart
Frankfurt
As of 4:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

response biomedical corp (RBM) Snapshot

Open
C$0.70
Previous Close
C$0.70
Day High
C$0.70
Day Low
C$0.70
52 Week High
08/13/14 - C$1.89
52 Week Low
12/31/14 - C$0.66
Market Cap
6.9M
Average Volume 10 Days
2.0K
EPS TTM
C$-0.58
Shares Outstanding
9.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RESPONSE BIOMEDICAL CORP (RBM)

Related News

No related news articles were found.

response biomedical corp (RBM) Related Businessweek News

No Related Businessweek News Found

response biomedical corp (RBM) Details

Response Biomedical Corp. engages in the research, development, commercialization, and distribution of diagnostic technologies for the medical central-lab testing, point of care (POC) testing, and on-site environmental testing markets. The POC and on-site diagnostic tests are non-laboratory based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges, and/or dipsticks. It provides RAMP system, which is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test. The company’s RAMP tests are used in the early detection of heart attack, congestive heart failure, influenza A+B, the respiratory syncytial virus, and environmental detection of West Nile Virus; and biodefense applications, including the rapid on-site detection of anthrax, smallpox, ricin, and botulinum toxin. Response Biomedical Corp. sells its products through distributors primarily in the United States, Asia, the Latin America, Europe, South America, Canada, the Middle East, and internationally. The company was founded in 1980 and is headquartered in Vancouver, Canada.

68 Employees
Last Reported Date: 03/19/15
Founded in 1980

response biomedical corp (RBM) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: C$212.3K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$251.1K
Treasurer, Director and Member of Option Comm...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

response biomedical corp (RBM) Key Developments

Response Biomedical Promotes Dr. Barbara Kinnaird to CEO

The Board of Directors of Response Biomedical Corp. announced that Dr. Barbara Kinnaird has been elevated to the position of Chief Executive Officer, effective immediately. He is an Interim Chief Executive Officer since September 2014. Dr. Barbara Kinnaird has over 20 years of research and business experience primarily in the fields of point of care testing and in vitro diagnostics.

Response Biomedical Reports Earnings Results for the First Quarter Ended March 31, 2015

Response Biomedical reported earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported product sales of CAD 3,271,000 compared to CAD 2,559,000 a year ago. The increase was primarily due to higher instrument and cardiovascular test sales in China. Total revenue CAD 3,540,000 compared to CAD 2,559,000 a year ago. Adjusted net loss CAD 1,155,000 compared to CAD 1,362,000 a year ago. Net loss and comprehensive loss for the period CAD 1,100,000 compared to CAD 1,523,000 a year ago. The decrease in GAAP Net loss was primarily due to higher gross profit due to the increase in collaborative revenue and the decrease in operating expenses. Loss per basic and diluted share was CAD 0.11 compared to CAD 0.19 a year ago. Adjusted EBITDA was CAD 658,000 compared to CAD 819,000 a year ago. Adjusted net loss was CAD 1,155,000 compared to CAD 1,362,000 a year ago.

Response Biomedical Corp. to Report Q1, 2015 Results on May 05, 2015

Response Biomedical Corp. announced that they will report Q1, 2015 results Pre-Market on May 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBM:CN C$0.70 CAD 0.00

RBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $152.43 USD +0.28
Cepheid $56.00 USD +0.41
Quidel Corp $20.62 USD -0.09
Siemens AG €98.21 EUR +0.094
View Industry Companies
 

Industry Analysis

RBM

Industry Average

Valuation RBM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESPONSE BIOMEDICAL CORP, please visit www.responsebio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.